WHO Pharmaceuticals Newsletter 2003, No. 03
(2003; 14 pages) Voir le document au format PDF
Table des matières
Ouvrir ce répertoire et afficher son contenuREGULATORY MATTERS
Fermer ce répertoireSAFETY OF MEDICINES
Afficher le documentANTIRETRO-VIRALS - Benefit/Risk balance remains strongly positive for combination antiretroviral therapy
Afficher le documentCYPROTERONE ACETATE & ETHINYL-ESTRADIOL - Update on risk of venous thromboembolism
Afficher le documentDIETHYL-STILBESTROL - Gynaecological and obstetric complications after in utero exposure
Afficher le documentEPHEDRA - Moves to reduce risks of ephedra-containing products
Afficher le documentFLUTICASONE PROPIONATE - Reports of adrenal crisis
Afficher le documentGRAPEFRUIT JUICE - Revised advice from ADRAC
Afficher le documentHORMONE REPLACEMENT THERAPY (HRT) - Risk of dementia
Afficher le documentOMEPRAZOLE, RABEPRAZOLE - Reports of interstitial nephritis
Afficher le documentROFECOXIB, CELECOXIB - Case reports support causal association with liver toxicity
Afficher le documentROSIGLITA-ZONE, PIOGLITAZONE - Adverse reactions update
Afficher le documentSOMATROPIN - Not to be authorized for AIDS-related wasting syndrome
Ouvrir ce répertoire et afficher son contenuCURRENT CONCERNS
Ouvrir ce répertoire et afficher son contenuDRUGS OF INTEREST
Ouvrir ce répertoire et afficher son contenuFEATURE

FLUTICASONE PROPIONATE - Reports of adrenal crisis

Australia. Adverse Drug Reactions Advisory Committee (ADRAC) in Australia has received 10 reports of inhaled corticosteroid-associated adrenal crisis. Eight cases involved children aged 3 10 years who had received fluticasone propionate (Flixotide) 250 1500 µg/day; in six cases, the daily dose was > 500µg, the upper limit recommended by The Thoracic Society of Australia and New Zealand and by The National Asthma Council in Australia, before referral to a respiratory physician. The committee notes that higher fluticasone propionate doses may not confer greater efficacy and prescribers are reminded that "inhaled corticosteroids should be given at the lowest effective dose and reviewed regularly".

Reports in WHO-file: Adrenal insufficiency 100

Australian Adverse Drug Reactions Bulletin 22: 6, Apr 2003.

vers la section précédente
vers la section suivante
Le Portail d'information - Médicaments essentiels et produits de santé a été conçu et est maintenu par l'ONG Human Info. Dernière mise à jour: le 1 décembre 2019